Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information...
-
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ustekinumab (Stelara) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
-
Dublin, Oct. 18, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Manufacturing Consumables Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's...
-
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Contract Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ...
-
Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
-
Samsung Bioepis Presents Totality-of-the-Evidence Supporting Extrapolation of EPYSQLI™ (SB12; Eculizumab)’s Indication, at the European Society of Paediatr
-
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Etanercept - Biosimilar Insight, 2024" report has been added to ResearchAndMarkets.com's offering.This "Etanercept - Biosimilar Insight, 2024" report...
-
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
-
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The "US Biosimilar Market: Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's offering.The US biosimilar market is...
-
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report